BD announces publication of drug-coated balloon safety data for femoropopliteal PAD

233
Lutonix
Lutonix drug coated balloon

BD has announced the publication of a company-initiated, independent analysis of the Lutonix 035 drug-coated balloon (DCB) femoropopliteal clinical programme in the Journal of the American College of Cardiology (JACC): Cardiovascular Interventions. These data were simultaneously presented in a late-breaking session at Transcatheter Cardiovascular Therapeutics (TCT; 24–29 September, San Francisco, USA), the annual scientific symposium of the Cardiovascular Research Foundation.

This independent analysis evaluated Lutonix 035 DCB (n=1,093) and standard percutaneous transluminal angioplasty (PTA; n=250) safety outcomes using patient-level data and propensity-matching from three Lutonix DCB randomised controlled trials: LEVANT 1, LEVANT 2, and LEVANT Japan, as well as the Continued Access cohort of the LEVANT 2 trial, and confirmed that there was no statistically significant increase in mortality with the use of LUTONIX 035 DCB.

“While the FDA and Advisory Committee of Circulatory System Devices Panel in June identified a late mortality signal after treatment with paclitaxel-coated devices using a meta-analysis of randomised controlled trials at five years from multiple companies, they recognised the benefits of these devices, including fewer reinterventions. They agreed that the magnitude of the signal should be interpreted with caution due to multiple limitations in the available data,” said Kenneth Ouriel, president and CEO, Syntactx, the clinical research firm that conducted the independent analysis, and former chairman of Surgery at the Cleveland Clinic.

He continued: “This large patient-level analysis found no statistically significant increase in mortality associated with LUTONIX DCB treatment. LUTONIX DCB remains a viable medical therapy for patients with peripheral arterial disease who demonstrate a high risk for restenosis and repeat femoropopliteal interventions.”

Further, a medical advisory committee comprised of an interventionalist and oncologist re-evaluated the cause of death in the LEVANT 1 and LEVANT 2 trials, including the LEVANT 2 Continued Access cohort. This independent review confirmed through adjudication that zero deaths were determined to be related to paclitaxel. Moreover, no clustering or pattern of death in any cardiovascular or non-cardiovascular categories was observed, which would have indicated a causal relationship between paclitaxel and death.

“The published patient-level analysis from Syntactx provides important information that health care providers can use to make an informed decision on the use of paclitaxel devices until additional long-term data are available,” said JD Meler, vice president of Medical and Clinical Affairs for BD’s Peripheral Intervention business. “Patient safety is our top priority, and BD remains committed to improving the quality of life of patients with PAD.”


LEAVE A REPLY

Please enter your comment!
Please enter your name here